BMS Plavix Case Ruling Affects $72 Million Talcum verdict

BMS Plavix Case Ruling Affects $72 Million Talcum verdict

Introduction

Based on the June 2017 Bristol-Myers Squibb case ruling, a Missouri Eastern District Court of Appeals reversed a $72 million Talcum powder state court jury verdict, announced in favor of the plaintiff's family against J&J. In this case, the plaintiff's lawyers had argued that the long-term use of J&J's cancer-linked products had caused the plaintiff to develop ovarian cancer that killed her, which won a favorable verdict.

The plaintiff of Birmingham, AL, was among the 65 plaintiffs to file lawsuits against the talcum powder maker in St. Louis Circuit Court. Apart from two Missouri plaintiffs, the rest of the lawsuits were from outside.

Citing the similarity in the Bristol-Myers Squibb case, non-California residents could not file claims there against the New York-based manufacturer; similarly, non-residents of Missouri failed to comply with the jurisdiction limitations, which led to the reversal of the verdict. Four other similar verdicts may be affected as J&J has appealed against all of them.